UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Annals of oncology, 2020-03, Vol.31 (3), p.334-351

2020

Volltextzugriff (PDF)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

British journal of cancer, 2013-01, Vol.108 (1), p.72-81

2013

Volltextzugriff (PDF)

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Annals of oncology, 2022-01, Vol.33 (1), p.114-116

2022

Volltextzugriff (PDF)

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

Oncogene, 2010-11, Vol.29 (47), p.6257-6266

2010

Volltextzugriff (PDF)

Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era

Breast cancer research and treatment, 2011-11, Vol.130 (1), p.345-351

2011

Volltextzugriff (PDF)

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

Cancer chemotherapy and pharmacology, 2015-03, Vol.75 (3), p.579-586

2015

Volltextzugriff (PDF)

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

British journal of cancer, 2014-05, Vol.110 (10), p.2434-2440

2014

Volltextzugriff (PDF)

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

British journal of cancer, 2010-03, Vol.102 (6), p.981-986

2010

Volltextzugriff (PDF)

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

The New England journal of medicine, 2018-07, Vol.379 (1), p.54-63

2018

Volltextzugriff (PDF)

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

Journal of cancer research and clinical oncology, 2017-06, Vol.143 (6), p.1053-1059

2017

Volltextzugriff (PDF)

The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis

Oncogene, 2017-07, Vol.36 (29), p.4135-4149

2017

Volltextzugriff (PDF)

Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

Annals of oncology, 2016-10, Vol.27, p.vi241-vi241

2016

Volltextzugriff (PDF)

Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems

British journal of cancer, 2012-11, Vol.107 (10), p.1672-1677

2012

Volltextzugriff (PDF)

Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer

Annals of oncology, 2007-01, Vol.18 (1), p.93-98

2007

Volltextzugriff (PDF)

Disseminated Peritoneal Leiomyomatosis Responds to Systemic Chemotherapy

Oncology, 2009-01, Vol.76 (1), p.55-58

2009

Volltextzugriff (PDF)

Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis

Carcinogenesis (New York), 2000-02, Vol.21 (2), p.331-335

2000

Volltextzugriff (PDF)

Medulloblastoma in adults: Treatment outcome, relapse patterns, and prognostic factors

Strahlentherapie und Onkologie, 2012-10, Vol.188 (10), p.878-886

2012

Volltextzugriff (PDF)

Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients

Oncogene, 2012-07, Vol.31 (29), p.3419-3430

2012

Volltextzugriff (PDF)

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

British journal of cancer, 2004-08, Vol.91 (3), p.453-458

2004

Volltextzugriff (PDF)

Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance

Blood cancer journal (New York), 2013-07, Vol.3 (7), p.e125-e125

2013

Volltextzugriff (PDF)

Organization-based performance measures of cancer care quality: core measure development for breast cancer in Taiwan

European journal of cancer care, 2008-01, Vol.17 (1), p.5-18

2008

Volltextzugriff (PDF)

Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development

Oncogene, 2016-04, Vol.35 (16), p.2133-2144

2016

Volltextzugriff (PDF)

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil leucovorin for locally advanced or metastatic carcinoma of the biliary tract

British journal of cancer, 2004-05, Vol.90 (9), p.1715-1719

2004

Volltextzugriff (PDF)

High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy

British journal of cancer, 1997-01, Vol.75 (3), p.464-465

1997

Volltextzugriff (PDF)

Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

British journal of cancer, 2004-10, Vol.91 (8), p.1561-1565

2004

Volltextzugriff (PDF)

1 – 25 von 250

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(246)
Mit Volltextzugriff
(225)

Publikationsform

Artikel
(250)

Sprache

Englisch
(250)

Erscheinungsjahr

n.n

Thema

Science & Technology
(245)
Life Sciences & Biomedicine
(244)
Humans
(215)
Biological And Medical Sciences
(142)
Female
(139)
Medical Sciences
(137)
Male
(126)
Middle Aged
(117)
Tumors
(99)
Adult
(95)
Aged
(91)
Pharmacology. Drug Treatments
(51)
Antineoplastic Agents
(49)
Chemotherapy
(41)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(37)
Treatment Outcome
(34)
Aged, 80 And Over
(33)
Animals
(33)
Prognosis
(33)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(24)
Anticancer Research
(21)
Cancer
(21)
British Journal Of Cancer
(16)
Oncogene
(14)
Cancer Research
(12)
Journal Of Clinical Oncology
(11)
Oncology
(11)
Annals Of Oncology
(9)
Cancer Epidemiology, Biomarkers & Prevention
(9)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis

Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems

Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer

Disseminated Peritoneal Leiomyomatosis Responds to Systemic Chemotherapy

Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis

Medulloblastoma in adults: Treatment outcome, relapse patterns, and prognostic factors

Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance

Organization-based performance measures of cancer care quality: core measure development for breast cancer in Taiwan

Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil leucovorin for locally advanced or metastatic carcinoma of the biliary tract

High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy

Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

Aktive Filter

Suchergebnisse filtern